Calcium-D-Glucarate for Health & Longevity - Quick Reference Sheet
evipedia.ai
← Back

Calcium-D-Glucarate for Health & Longevity

Created on 09/07/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

A calcium salt of a sugar acid, whose whole case rests on blocking a gut enzyme that undoes the liver's disposal tag on hormones and toxins. Animal work is extensive and consistent; no controlled human trial exists on any outcome. Safety looks unremarkable at the doses sold, with digestive upset the main complaint and a small calcium contribution. (Full Review)

Protocol

Standard dose
500–1,500 mg daily
Supplement labels and the Examine monograph cite a 1,500–3,000 mg range. Doses above 3 g daily are not used outside animal work.
Single versus split dosing
Split dosing preferred
Two or three smaller doses maintain gut enzyme suppression better than one large one.
Best time of day
Evening
Most common, on the reasoning that bile flow and gut transit through the night are when reabsorption would otherwise occur. No study has compared timings.
Time to effect
Gut enzyme suppression
Within hours
Gut enzyme suppression begins within hours of the first dose.
Hormone change
6 weeks
Any downstream hormone change would need one full clearance cycle to appear, so six weeks is the earliest sensible re-test point.

Benefits

Contraindications
  • Solid-organ transplant recipients taking mycophenolate or another glucuronidated immunosuppressant
  • History of calcium-containing kidney stones or hypercalciuria (urine calcium above 250 mg/day in women, 300 mg/day in men)
  • Primary hyperparathyroidism or albumin-corrected serum calcium above 10.5 mg/dL
  • Chronic kidney disease at stage 4 or worse (filtration rate below 30 mL/min/1.73 m²)
  • Pregnant or breastfeeding women
  • Already-low sex hormones (estradiol below 20 pg/mL, or total testosterone below 300 ng/dL)
  • Lamotrigine or another antiepileptic with a narrow therapeutic window
    •
Key Interactions
  • Oral contraceptives and estrogen therapy (ethinylestradiol, estradiol, conjugated estrogens)
  • Opioid analgesics (morphine, hydromorphone)
  • Irinotecan and regorafenib
  • Drugs requiring calcium separation (levothyroxine, tetracyclines, fluoroquinolones, oral bisphosphonates)
  • Acetaminophen
  • Non-steroidal anti-inflammatory drugs (ibuprofen, naproxen, diclofenac)
  • Calcium-containing antacids (calcium carbonate), calcium supplements and calcium-fortified foods
  • Iron and zinc
  • Sulforaphane, indole-3-carbinol and diindolylmethane
  • Milk thistle, curcumin and green tea catechins
  • Testosterone or estrogen replacement therapy
  • Aromatase inhibitors (anastrozole, letrozole)
    •

Risk & Side Effects

  • High:
  • Medium:
  • Low: Reduced exposure to medicines cleared by glucuronidation; incremental calcium load; gastrointestinal discomfort
  • Speculative: Suppression of circulating sex hormones; disruption of neurotransmitter and hormone recycling in the gut; unknown fetal and neonatal exposure effects

Monitoring

Marker Target Why
Estradiol Premenopausal follicular 30–100 pg/mL; postmenopausal 20–40 pg/mL The hormone the compound is most often taken to clear
Total testosterone Men 600–900 ng/dL; women 30–60 ng/dL Androgens leave by the same route and can fall alongside estrogen
Sex hormone–binding globulin 20–60 nmol/L Sets how much hormone is free, and therefore how much any clearance change actually matters
Urinary estrogen metabolites (2-hydroxy to 16-alpha-hydroxy ratio) Above 2.0 Shows the direction estrogen is being broken down, not only how much is present
Stool beta-glucuronidase activity No established universal target; track the change from the individual's own pre-treatment baseline The enzyme the compound is meant to inhibit, and the only direct read on target engagement
Serum calcium, albumin-corrected 9.0–9.7 mg/dL Detects calcium accumulation from this salt stacked on other supplements
Fasting lipid panel (LDL cholesterol, triglycerides) LDL cholesterol below 100 mg/dL; triglycerides below 100 mg/dL The only human outcome ever attributed to this compound
Liver enzymes Alanine aminotransferase 10–26 U/L; aspartate aminotransferase 10–26 U/L Confirms no hepatic strain from a compound marketed for liver support
Estimated glomerular filtration rate and 24-hour urine calcium Filtration rate above 90 mL/min/1.73 m²; urine calcium below 250 mg/day in women and 300 mg/day in men Screens for the stone and kidney risk carried by the calcium component

Cadence: Baseline panel before starting. Hormones and lipids repeated at six weeks, then at six months, then annually. Serum calcium and kidney function at three months and annually thereafter, or sooner if total supplemental calcium rises. Where a medicine cleared by glucuronidation is in use, that drug's level or clinical effect is reviewed at two and six weeks.

Qualitative Assessment

  • Cycle regularity, flow volume and premenstrual breast tenderness in menstruating women
  • Skin clarity and oiliness, which often tracks androgen and estrogen balance
  • Bowel frequency and stool form, since transit time governs how long reabsorption has to occur
  • Libido and morning erections in men, as an early signal of over-clearance of testosterone
  • Energy stability across the day and subjective tolerance of alcohol or medication
  • Any change in the felt potency or duration of a regular medication
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.